251 related articles for article (PubMed ID: 24094599)
1. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
3. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.
Connolly MP; Boersma C; Oldenburg B
Neth J Med; 2012 Aug; 70(6):272-7. PubMed ID: 22859419
[TBL] [Abstract][Full Text] [Related]
4. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial.
Connolly MP; Nielsen SK; Currie CJ; Poole CD; Travis SP
J Crohns Colitis; 2009 Feb; 3(1):32-7. PubMed ID: 21172245
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
Brereton N; Bodger K; Kamm MA; Hodgkins P; Yan S; Akehurst R
J Med Econ; 2010 Mar; 13(1):148-61. PubMed ID: 20141380
[TBL] [Abstract][Full Text] [Related]
6. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis.
Buckland A; Bodger K
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1287-96. PubMed ID: 18808444
[TBL] [Abstract][Full Text] [Related]
7. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A
J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Zheng X; Zhang Z; Wang B; Li J; Qiu C; Zhang Q; Wang X
Medicine (Baltimore); 2019 Apr; 98(14):e15113. PubMed ID: 30946380
[TBL] [Abstract][Full Text] [Related]
9. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial.
Connolly MP; Nielsen SK; Currie CJ; Marteau P; Probert CS; Travis SP
J Crohns Colitis; 2009 Sep; 3(3):168-74. PubMed ID: 21172266
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM
BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262
[TBL] [Abstract][Full Text] [Related]
13. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
14. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
[TBL] [Abstract][Full Text] [Related]
15. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
16. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
17. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
Tong JL; Huang ML; Xu XT; Qiao YQ; Ran ZH
J Dig Dis; 2012 Apr; 13(4):200-7. PubMed ID: 22435504
[TBL] [Abstract][Full Text] [Related]
18. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain].
Gisbert JP; Gomollón F; Méndez I
Gastroenterol Hepatol; 2016 Mar; 39(3):199-212. PubMed ID: 26072136
[TBL] [Abstract][Full Text] [Related]
20. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
